Bio-Rad Laboratories, Inc. BIO.B Clinical Diagnostics — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GoodwillGross.
The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories, Inc.'s clinical diagnostics — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories, Inc.'s clinical diagnostics — goodwill?
- Bio-Rad Laboratories, Inc. (BIO.B) reported clinical diagnostics — goodwill of $421.8M in Q1 2026.
- How has Bio-Rad Laboratories, Inc.'s clinical diagnostics — goodwill changed year-over-year?
- Bio-Rad Laboratories, Inc.'s clinical diagnostics — goodwill increased by 1.3% year-over-year, from $416.5M to $421.8M.
- What is the long-term trend for Bio-Rad Laboratories, Inc.'s clinical diagnostics — goodwill?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories, Inc.'s clinical diagnostics — goodwill has grown at a 4.7% compound annual growth rate (CAGR), from $1.4B to $1.68B.
- What does clinical diagnostics — goodwill mean?
- The total value of goodwill attributed to the Clinical Diagnostics business unit.
- How do you interpret clinical diagnostics — goodwill?
- An increase suggests recent acquisitions within the diagnostics space, while a decrease may indicate impairment or divestiture.
- How does clinical diagnostics — goodwill compare across companies?
- Common in life sciences and diagnostics firms that grow through M&A; peers often report this by segment.